Charles Schwab Investment Management Inc. lifted its stake in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 4.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 361,812 shares of the health services provider’s stock after acquiring an additional 15,730 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.10% of Amedisys worth $32,849,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. SRS Capital Advisors Inc. raised its stake in shares of Amedisys by 2,298.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,319 shares of the health services provider’s stock worth $120,000 after purchasing an additional 1,264 shares in the last quarter. US Bancorp DE raised its position in Amedisys by 5.7% during the fourth quarter. US Bancorp DE now owns 3,916 shares of the health services provider’s stock valued at $356,000 after acquiring an additional 210 shares in the last quarter. Amalgamated Bank lifted its stake in Amedisys by 2.9% in the fourth quarter. Amalgamated Bank now owns 15,593 shares of the health services provider’s stock valued at $1,416,000 after acquiring an additional 444 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Amedisys by 22.6% in the fourth quarter. Bank of New York Mellon Corp now owns 298,870 shares of the health services provider’s stock worth $27,134,000 after purchasing an additional 55,073 shares in the last quarter. Finally, South Dakota Investment Council boosted its stake in shares of Amedisys by 5.2% during the 4th quarter. South Dakota Investment Council now owns 50,841 shares of the health services provider’s stock worth $4,616,000 after acquiring an additional 2,500 shares in the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys Stock Performance
AMED opened at $92.57 on Monday. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The firm has a market capitalization of $3.04 billion, a P/E ratio of 36.73, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. The stock’s 50 day moving average price is $92.14 and its two-hundred day moving average price is $92.75. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.
Wall Street Analysts Forecast Growth
Separately, Stephens reaffirmed an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Amedisys presently has a consensus rating of “Hold” and a consensus price target of $100.75.
Read Our Latest Research Report on Amedisys
Amedisys Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Read More
- Five stocks we like better than Amedisys
- Dividend Payout Ratio Calculator
- How to Build the Ultimate Everything ETF Portfolio
- Consumer Discretionary Stocks Explained
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.